AI can be applied to patient data in real time, allowing medical reviewer teams to actively monitor patient safety, with the AI alerting medical review teams to identify potential adverse events (AEs), data anomalies, critical issues for patients on treatment, and more.
Related Posts
Ensuring Consistency with Lab Testing
In a recent interview with Applied Clinical Trials, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, discussed the benefits…
Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS
Credit: ralwel | stock.adobe.com Results from the Phase III HERCULES (NCT04411641) trial and Phase III GEMINI 1 (NCT04410978) and GEMINI…
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
Credit: Mopic | stock.adobe.com The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to postoperative chemotherapy was not found to…